Skip to Content
Merck
CN

69037

Sigma-Aldrich

Ureidosuccinic acid

98.0-102.0% (T)

Synonym(s):

N-Carbamoyl-DL-aspartic acid

Sign Into View Organizational & Contract Pricing

About This Item

Linear Formula:
HOOCCH2CH(NHCONH2)COOH
CAS Number:
923-37-5
Molecular Weight:
176.13
Beilstein:
1726861
EC Number:
213-096-6
MDL number:
MFCD00042822
UNSPSC Code:
12352106
PubChem Substance ID:
329761332
NACRES:
NA.25

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

Assay

98.0-102.0% (T)

mp

~175 °C (dec.)

format

neat

SMILES string

NC(=O)NC(CC(O)=O)C(O)=O

InChI

1S/C5H8N2O5/c6-5(12)7-2(4(10)11)1-3(8)9/h2H,1H2,(H,8,9)(H,10,11)(H3,6,7,12)

InChI key

HLKXYZVTANABHZ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Metabolite of pyrimidine biosynthesis, alanine, aspartate and glutamate metabolism.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCC6902
BCBP9233V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

L D Fairbanks et al.
Journal of chromatography. B, Biomedical sciences and applications, 732(2), 487-493 (1999-10-12)
Leflunomide is an immunomodulatory drug which acts by inhibiting dihydroorotic acid dehydrogenase, the fourth enzyme of pyrimidine biosynthesis. We modified our high-performance liquid chromatography method to demonstrate that the principal metabolite in mitogen-stimulated human T-lymphocytes incubated with leflunomide was not
André B P van Kuilenburg et al.
Clinical chemistry, 50(11), 2117-2124 (2004-09-18)
The concentrations of the pyrimidine "de novo" metabolites and their degradation products in urine are useful indicators for the diagnosis of an inborn error of the pyrimidine de novo pathway or a urea-cycle defect. Until now, no procedure was available
Amy J Rice et al.
Analytical biochemistry, 441(1), 87-94 (2013-06-19)
Dihydroorotase (DHOase) is the third enzyme in the de novo pyrimidine biosynthesis pathway and is a potential new antibacterial drug target. No target-based high-throughput screening (HTS) assay for this enzyme has been reported to date. Here, we optimized two colorimetric-based
S Vasudevan et al.
Carcinogenesis, 15(11), 2497-2500 (1994-11-01)
Feeding excess orotic acid (OA) in the diet promotes the carcinogenic process in different organs including the liver. A number of metabolic and genetic disorders are associated with increased synthesis of endogenous OA and some of these disorders appear to
André Brannvoll et al.
Cell reports, 32(1), 107849-107849 (2020-07-09)
Replication-blocking DNA lesions are particularly toxic to proliferating cells because they can lead to chromosome mis-segregation if not repaired prior to mitosis. In this study, we report that ZGRF1 null cells accumulate chromosome aberrations following replication perturbation and show sensitivity
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service